Ascletis' ASC37 shows 88% greater weight loss than tirzepatide
July 28, 2026 | 14:47
Ascletis reported its triple peptide agonist ASC37 demonstrated a statistically significant 88 per cent greater relative body weight reduction than tirzepatide in a diet-induced obese mouse model.
Mobile Version